| Literature DB >> 26329643 |
Shulan Su1,2, Jinao Duan1,2, Ting Chen1,2, Xiaochen Huang1,2, Erxin Shang1,2, Li Yu1,2, Kaifeng Wei3, Yue Zhu1,2, Jianming Guo1,2, Sheng Guo1,2, Pei Liu1,2, Dawei Qian1,2, Yuping Tang1,2.
Abstract
Frankincense and myrrh are highly effective in treatment of inflammatory diseases, but lacking of thetherapy mechanisms. We undertook this study to evaluate the effects on Adjuvant-induced Arthritis(AIA) rats and to explore the underlying mechanisms by analyzing the metabolic profiling and signalingpathway evaluated by expression of inflammatory cytokines, c-jun and c-fos and corresponding phosphorylationlevels. [corrected]. The results stated the elevated expression levels of TNFα, PGE2, IL-2, NO, and MDA in serum and swelling paw of AIA rats were significantly decreased after treatment, which exerted more remarkable inhibitive effects of combined therapy. The metbolic profiling of plasma and urine were clearly improved and twenty-one potential biomarkers were identified. Moreover, the inhibited effects of five bioactive components on cytokine transcription in PHA stimulated-PBMC showed the MAPK pathway might account for this phenomenon with considerable reduction in phosphorylated forms of all the three MAPK (ERK1/2, p38 and JNK) and down regulation of c-jun and c-fos.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26329643 PMCID: PMC4556964 DOI: 10.1038/srep13668
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1The chemical structures of five bioactive compounds drived from Frankincense (compounds 1, 4, and 5) and Myrrh (compounds 2 and 3) (1. 3-hydroxylanosta-8,24-dien-21-oic-acid; 2. 2-Methoxy-5-acetoxy-fruranogermacr -1(10)-en-6-one; 3. abietic acid; 4. elemonic acid; 5. Acetyl elemolic acid).
Effects of extracts of C. myrrha, B. carterii. and their combination on rat hind paw swelling in adjuvant-induced arthritis model.
| Groups | Dosage(mg/Kg·d p.o.) | Rat hind paw volume in ml ± SD (% inhibition) | |||||
|---|---|---|---|---|---|---|---|
| Day 0 | Day 13 | Day 20 | Day 24 | Day 27 | Day 30 | ||
| Group-I | – | 0.86 ± 0.12 | 1.03 ± 0.10 | 1.04 ± 0.07 | 1.06 ± 0.07 | 1.16 ± 0.43 | 0.96 ± 0.15 |
| Group-II | – | 0.863 ± 0.16 | 1.87 ± 0.15 | 1.86 ± 0.13 | 1.86 ± 0.12 | 1.89 ± 0.12 | 2.00 ± 0.13 |
| Group-III | 10 | 0.83 ± 0.21 | 1.73 ± 0.15 | 1.61 ± 0.13 | 1.54 ± 0.15 | 1.47 ± 0.05 | 1.38 ± 0.06 |
| Group-IV | 54.28 | 0.85 ± 0.23 | 1.75 ± 0.19 | 1.61 ± 0.12 | 1.48 ± 0.08 | 1.42 ± 0.05 | 1.38 ± 0.05 |
| Group-V | 90.48 | 0.80 ± 0.20 | 1.70 ± 0.15 | 1.64 ± 0.12 | 1.58 ± 0.11 | 1.46 ± 0.12 | 1.36 ± 0.074 |
| Group-VI | 33.67 | 0.82 ± 0.21 | 1.78 ± 0.16 | 1.67 ± 0.08 | 1.55 ± 0.15 | 1.49 ± 0.11 | 1.47 ± 0.13 |
| Group-VII | 56.12 | 0.86 ± 0.18 | 1.88 ± 0.27 | 1.79 ± 0.20 | 1.56 ± 0.27 | 1.49 ± 0.20 | 1.39 ± 0.13 |
| Group-VIII | 46.15 | 0.87 ± 0.16 | 1.87 ± 0.17 | 1.78 ± 013 | 1.63 ± 0.23 | 1.53 ± 0.14 | 1.48 ± 0.09 |
| Group-IX | 76.92 | 0.85 ± 0.15 | 1.78 ± 0.19 | 1.69 ± 0.11 | 1.53 ± 0.15 | 1.43 ± 0.18 | 1.36 ± 0.14 |
Values are expressed as mean ± S.D., n = 8 animals in each group. Figures in parenthesis indicate percent inhibition of rats paw volume of FCA and drug treated groups Vs healthycontrol Group. Comparisons were made between: a-Group I vs GroupII- IX. B-Group II vs Group III–IX. (*P < 0.05, **P < 0.01, ***P < 0.001).
Effects of Frankincense, Myrrh and combined extracts on the cytokines (NO, MDA, IL-2, PGE2, TNF) levels in rats’serum and right paw swelling of adjuvant-induced arthritia model (, n = 8).
| Groups | Dosagemg/Kg·d | NO ( | MDA (nmol/Ml) | IL-2 (pg/mL) | PGE2(pg/mL) | TNFα(pg/mL) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| In serum | Right paw tissue | In serum | Rightpawtissue | In serum | Rightpawtissue | In serum | Rightpawtissue | In serum | Rightpawtissue | ||
| Group-I | — | 73.72 ± 6.34 | 83.24 ± 10.86 | 32.47 ± 3.10 | 0.61 ± 0.08 | 48.56 ± 7.93 | 53.41 ± 13.71 | 174.05 ± 14.46 | 84.55 ± 18.74 | 24.68 ± 3.87 | 40.49 ± 2.86 |
| Group-II | — | 153.12 ± 10.22 | 120.08 ± 10.29 | 41.96 ± 1.76 | 3.40 ± 0.48 | 143.10 ± 8.06 | 110.35 ± 11.77 | 459.29 ± 22.86 | 444.19 ± 10.39 | 110.35 ± 11.78 | 94.72 ± 25.67 |
| Group-III | 10.00 | 94.99 ± 10.89 | 67.67 ± 7.49 | 33.74 ± 2.90 | 0.80 ± 0.16 | 79.39 ± 15.33 | 72.00 ± 25.17 | 220.76 ± 22.15 | 123.50 ± 15.48 | 47.81 ± 5.39 | 44.40 ± 10.51 |
| Group-IV | 54.28 | 144.61 ± 25.99 | 78.16 ± 7.93 | 36.38 ± 4.01 | 0.95 ± 0.06 | 97.75 ± 17.33 | 86.56 ± 10.66 | 229.56 ± 15.65 | 303.96 ± 54.17 | 38.95 ± 11.22 | 49.35 ± 9.65 |
| Group-V | 90.48 | 92.15 ± 8.39 | 54.66 ± 5.61 | 38.24 ± 4.83 | 2.47 ± 0.57 | 65.22 ± 8.33 | 71.40 ± 15.31 | 345.77 ± 18.36 | 156.23 ± 18.25 | 66.42 ± 11.01 | 35.81 ± 7.49 |
| Group-VI | 33.67 | 86.48 ± 13.52 | 60.94 ± 3.98 | 40.20 ± 7.57 | 2.34 ± 0.48 | 168.42 ± 13.12 | 97.52 ± 8.29 | 342.97 ± 43.92 | 277.43 ± 25.34 | 69.44 ± 9.41 | 55.71 ± 4.58 |
| Group-VII | 56.12 | 114.84 ± 13.52 | 71.18 ± 14.62 | 38.53 ± 5.20 | 2.17 ± 0.48 | 96.40 ± 10.17 | 63.30 ± 7.61 | 354.70 ± 34.30 | 159.32 ± 26.11 | 58.93 ± 7.66 | 37.39 ± 6.11 |
| Group-VIII | 46.15 | 121.93 ± 27.49 | 73.72 ± 2.52 | 37.85 ± 4.81 | 1.91 ± 0.27b *** | 88.02 ± 8.56 | 77.11 ± 18.44 | 350.71 ± 11.39 | 188.96 ± 20.33 | 60.68 ± 10.39 | 44.63 ± 8.20 |
| Group-IX | 76.92 | 62.38 ± 24.23 | 46.79 ± 6.70 | 35.11 ± 1.24 | 1.57 ± 0.30 | 44.84 ± 11.51 | 60.52 ± 10.68 | 304.01 ± 22.97 | 263.73 ± 33.99 | 35.87 ± 7.28 | 31.80 ± 5.98 |
Results were expressed as mean ± standard deviation of 8 animals per group (n = 8). Comparisons were made between: (a) Group I vs GroupII–IX. (b) GroupII vs Group III–IX. Symbols represent statistical significance: *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 2PCA model results between AIA rats and controls in negative mode.
((A) 2-D plot of plasma; (B) 2-D plot of urine). 3D PLS-DA scores plot of LC–MS spectral data ((C) plasma, R2 = 0.87, Q2 = 0.92; (D) urine, R2 = 0.93, Q2 = 0.88). S-plot of OPLS-DA model for AIA vs control group. ((E) plasma, R2 = 0.86, Q2 = 0.81; (F) urine, R2 = 0.96, Q2 = 0.84). PCA analytical results from AIA rats treated with drugs in different groups at negative mode. ((G) For plasma; (H) for urine).
The identified and change trend of the potential biomarkers of AIA rats intervened by frankincense and myrrh.
| No. | tR/min | [M-H]− | metabolites | Contentvariance | Effects of test drugs | Pathway (KEGG) | Resources | |||
|---|---|---|---|---|---|---|---|---|---|---|
| GroupIII | GroupV | GroupVII | GroupIX | |||||||
| 1 | 10.75 | 568.3625 | LysoPC(17:0) | ↓ | ↑ | ↑ | – | – | Glycerophospholipid metabolism | Plasma |
| 2 | 8.56 | 540.3321 | LysoPC(15:0) | ↓ | ↑ | ↑ | – | – | Glycerophospholipid metabolism | Plasma |
| 3 | 7.81 | 564.3312 | LysoPE(20:2(11Z,14Z)/0:0) | ↓ | ↑ | ↑ | ↑ | ↑ | Glycerophospholipid metabolism | Plasma |
| 4 | 9.04 | 566.3466 | LysoPE(20:1(11Z)/0:0) | ↓ | ↑ | ↑ | ↑ | ↑ | Glycerophospholipid metabolism | Plasma |
| 5 | 7.27 | 538.3158 | LysoPE(18:1(9Z)/0:0) | ↓ | ↑ | ↑ | ↑ | – | Glycerophospholipid metabolism | Plasma |
| 6 | 6.36 | 312.0784 | Alanyl tryptophan | ↑ | ↓ | ↓ | ↓ | ↓ | Tryptophan metabolism | Plasma |
| 7 | 7.49 | 564.3321 | LysoPC(18:2(9Z,12Z)) | ↓ | ↑ | ↑ | ↑ | ↓↓ | Glycerophospholipid metabolism | Plasma |
| 8 | 13.21 | 279.2318 | Linoelaidic acid | ↑ | ↓ | ↓ | ↓ | ↓ | Biosynthesis of unsaturated fatty acids | Plasma |
| 9 | 12.50 | 327.2319 | Docosahexaenoic acid | ↑ | ↓ | ↓ | ↓ | ↓ | Biosynthesis of unsaturated fatty acids | Plasma |
| 10 | 9.75 | 554.3479 | LysoPC(16:0/0:0) | ↓ | ↑ | ↑ | – | ↑ | Glycerophospholipid metabolism | Plasma |
| 11 | 6.74 | 160.0394 | 4,6-Dihydro xyquinoline | ↓ | ↑ | – | ↑ | ↑ | 5-hydroxytryptophan metabolism | Urine |
| 12 | 5.27 | 284.0589 | Malonyl carnitine | ↓ | ↑ | ↑ | ↑ | ↑ | Fatty acid metabolism | Urine |
| 13 | 3.15 | 242.0115 | Bicine | ↓ | ↑ | ↑ | ↑ | ↑ | Urine | |
| 14 | 2.45 | 230.0109 | Homocysteine thiolactone | ↓ | ↑ | ↑ | ↑ | ↑ | Amino acid biosynthesis | Urine |
| 15 | 1.02 | 191.0173 | Citric acid | ↓ | ↑ | ↑ | – | – | Citrate cycle (TCA cycle) | Urine |
| 16 | 8.16 | 268.0634 | Isoval eryglutamic acid | ↓ | ↑ | ↑ | – | – | Urine | |
| 17 | 0.76 | 191.0183 | Glucaric acid | ↓ | ↑ | ↑ | – | – | Glyoxylate and dicarboxylate metabolism | Urine |
| 18 | 14.35 | 408.1657 | 9′-carboxy-gama-tocotrienol | ↓ | ↑ | ↑ | – | – | Glyoxylate and dicarboxylate metabolism | Urine |
| 19 | 7.08 | 338.0893 | Topiramate | ↓ | – | ↑ | – | – | Urine | |
| 20 | 13.92 | 343.0847 | Xanthosine | ↓ | ↑ | ↑ | – | – | Purine metabolism | Urine |
| 21 | 4.51 | 212.0017 | Indoxyl sulfate | ↑ | ↓ | ↓ | ↓ | ↓ | Tryptophan metabolism | Urine |
a. P-values were calculated from two-tailed Mann–Whitney U-test with a threshold of 0.05. b↑, content increased and p < 0.05; c↓, content decreased and p < 0.05. d. Confirmed by standard samples.
Figure 3(A) Analysis of compounds 1–5 on PHA induced proinflammatory cytokine expression in PBMC. PBMCs were induced with PHA (10 ng/ml) for 6 hours and inhibitory effect of them on cytokines expression was studied by RT-PCR analysis. (B) Analysis of compounds 1–5 on MAPK. (a) non-phospho ERK, (b) Phospho-ERK, (c) non-phospho JNK, (d) Phospho-JNK, (e) non-phospho p38, (f) Phospho-p38. By Western blotting, the inhibitory effects of them on active forms of MAP kinases were analysed in PHA stimulated PBMC, using antibodies recognizing the phosphorylated and non-phophorylated forms of ERK1/2, JNK and p38 MAPK. (C) Analysis of compounds 1–5 on PHA induced c-fos and c-jun expression in PBMC. PBMCs were induced with PHA (10 ng/ml) for 6 hours and inhibitory effect of the five compounds on c-fos and c-jun cytokines expression was studied.
Figure 4Correlation networks of main potential biomarkers in response to AIA and the effects of treatment for AIA.
The metabolites marked in red denote the identified potential biomarkers.